Invivyd, Inc. Files 8-K on Financials and Operations

Ticker: IVVD · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1832038

Invivyd, INC. 8-K Filing Summary
FieldDetail
CompanyInvivyd, INC. (IVVD)
Form Type8-K
Filed DateMar 25, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-condition, operations

TL;DR

Invivyd dropped an 8-K detailing its financials and operations as of March 22nd.

AI Summary

Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on March 25, 2024, reporting on events as of March 22, 2024. The filing pertains to results of operations, financial condition, and other events, including financial statements and exhibits. The company is incorporated in Delaware and headquartered in Waltham, MA.

Why It Matters

This 8-K filing provides an update on Invivyd's operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on operational and financial matters, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Invivyd, Inc.?

The primary purpose is to report on Invivyd, Inc.'s results of operations and financial condition, as well as other events, and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was as of March 22, 2024.

What was Invivyd, Inc.'s former name?

Invivyd, Inc.'s former name was Adagio Therapeutics, Inc.

Where are Invivyd, Inc.'s principal executive offices located?

Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.

What is the SEC file number for Invivyd, Inc.?

The SEC file number for Invivyd, Inc. is 001-40703.

Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-03-22 20:58:35

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 22, 2024 99.2 Press Release, dated March 22, 2024 99.3 Corporate Presentation, dated March 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: March 22, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing